Home › Chronic Inflammatory Demyelinating Polyradiculoneuropathy › Ohio
Chronic Inflammatory Demyelinating Polyradiculoneuropathy clinical trials in Ohio
6 studies for Chronic Inflammatory Demyelinating Polyradiculoneuropathy are looking for participants at sites in Ohio.
Cities in Ohio
Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Site Number - 1624, Canton
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07032662A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
- University of Cincinnati Health, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06920004A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
- Clinical Study Site, Cincinnati
- Clinical Study Site, Columbus
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Oct 28, 2026 · NCT06858579A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- TG Therapeutics Investigational Trial Site, Cleveland
- TG Therapeutics Investigational Trial Site, Columbus
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 27, 2026 · NCT06680037A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- University of Cincinnati Medical Center- Site Number : 8400020, Cincinnati
- University Hospitals Cleveland Medical Center- Site Number : 8400033, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT06290141A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Cleveland Clinic, Cleveland
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jan 20, 2026 · NCT06747351From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.